Imperial Ginseng Products Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Imperial Ginseng Products hat ein Gesamteigenkapital von CA$360.7K und eine Gesamtverschuldung von CA$0.0, was einen Verschuldungsgrad von 0% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen CA$393.5K bzw. CA$32.8K.

Wichtige Informationen

Verhältnis von Schulden zu Eigenkapital

CA$0

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	CA$369.57k
Eigenkapital	CA$360.73k
Gesamtverbindlichkeiten	CA$32.81k
Gesamtvermögen	CA$393.54k

Jüngste Berichte zur Finanzlage

Keine Aktualisierungen

Recent updates

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: IGPDie kurzfristigen Aktiva des Unternehmens (CA$393.5K) übersteigen seine kurzfristigen Passiva (CA$32.8K).

Langfristige Verbindlichkeiten: IGP hat keine langfristigen Verbindlichkeiten.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: IGP ist schuldenfrei.

Schulden abbauen: IGP hat keine Schulden im Vergleich zu vor 5 Jahren, als das Verhältnis von Schulden zu Eigenkapital 10% betrug.

Schuldendeckung: IGP hat keine Schulden und muss daher nicht durch den operativer Cashflow gedeckt werden.

Zinsdeckung: IGP hat keine Schulden, daher ist die Deckung der Zinszahlungen kein Problem.

Imperial Ginseng Products Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Recent updates

First half 2024 earnings released: CA$0.005 loss per share (vs CA$0 in 1H 2023)

Upcoming dividend of CA$2.25 per share

Imperial Ginseng Products Ltd. Announces Cash Distribution, Payable on January 26, 2024

Investor sentiment improves as stock rises 27%

New major risk - Market cap size

Insufficient new directors

First quarter 2024 earnings released: CA$0.015 loss per share (vs CA$0.11 loss in 1Q 2023)

New major risk - Market cap size

Insufficient new directors

Here's Why We Think Imperial Ginseng Products (CVE:IGP) Is Well Worth Watching

Full year 2023 earnings released: EPS: CA$0.38 (vs CA$0.31 in FY 2022)

Imperial Ginseng Products Ltd., Annual General Meeting, Dec 07, 2023

Insufficient new directors

Third quarter 2023 earnings released: CA$0.03 loss per share (vs CA$0.05 loss in 3Q 2022)

Insufficient new directors

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CA$0.11 (vs CA$0.07 loss in 2Q 2022)

First quarter 2023 earnings released: CA$0.11 loss per share (vs CA$0.22 profit in 1Q 2022)

Insufficient new directors

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: CA$0.31 (vs CA$0.61 loss in FY 2021)

Imperial Ginseng Products Ltd., Annual General Meeting, Dec 07, 2022

Less than half of directors are independent

Chairman exercised options to buy CA$50k worth of stock.

Less than half of directors are independent

Third quarter 2022 earnings released: CA$0.05 loss per share (vs CA$0.03 loss in 3Q 2021)

Less than half of directors are independent

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Investor sentiment improved over the past week

We Think Imperial Ginseng Products' (CVE:IGP) Robust Earnings Are Conservative

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: CA$0.61 loss per share (vs CA$1.00 loss in FY 2020)

Less than half of directors are independent

Third quarter 2021 earnings released: CA$0.03 loss per share (vs CA$0.11 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CA$0.13 (vs CA$0.07 loss in 2Q 2020)

New 90-day high: CA$0.55

How Much is Imperial Ginseng Products' (CVE:IGP) CEO Getting Paid?

New 90-day high: CA$0.37

First quarter 2021 earnings released: CA$0.57 loss per share

Full year earnings released - CA$1.00 loss per share

Analyse der Finanzlage

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Bilanz

Entdecken Sie finanziell stabile Unternehmen